This article follows the brief history of the remdésivir (GS-5734) : a molecule of therapeutic interest is very questionable on the COVID-19. This molecule is made by the company Gilead, on which we have questioned the role played in the #LancetGate (this reference journal that published a study fraudulent before it was withdrawn by its authors) and the CoronaPapers. The cost of development of the molecule Remdesivir is very high without no benefit of a patient is shown. “A glimmer of hope,” said the professor Mehra before that his study cannot be retracted.
Lobbying or irrigation in all directions of Gilead
The great technique of Gilead to advance the remdésivir that we should not forget that proved to be a failure in the treatment of Ebola has been with the SARS-CoV2 of concreting, upon the development of the epidemic in China, the implementation of the approval of the remdésivir as a treatment of the disease in the USA and in Europe. Which, incidentally, clearly proves that in the circles informed we were confident that the epidemic in china was going to turn into a global pandemic striking the West with crazy money that a treatment could yield. For this it was necessary first that the remdésivir is tested by means of major research hospitals, within the framework of care it on compassionate, in hopeless cases in intensive care. The article published in the NEJM which tells the story of this phase of drug development (usually referred to as phase 0/1) reported a cohort of 53 patients who would have received the remdésivir on a mode that is compassionate, distributed in the world : United States (22 patients), Japan (9), Italy (12), Austria (1), France (4), Germany (2), Netherlands (1), Spain (1), and Canada (1). Not less than 57 researchers investigators have made a formal request to Gilead for the remdésivir (” Gilead Sciences began accepting requests from clinicians for compassionate use of remdesivir on January 25, 2020. “) !
Genesis of a promotion item remdésivir in the Lancet
We show in this section how a trial is conducted outside of Europe and not demonstrating any therapeutic activity statistically significant remdésivir has been published in the Lancet, a paragon of the scientific publication european medical.
The sponsor of this study in chinese, including the protocol test filed under id NCT04257656 on the official web site of the clinical trial registration US, ClinicalTrials.gov, is the Capital Medical University of Beijing.
A first version of the protocol of the trial NCT03257565 the results of which were published in the Lancet has been registered on the official website american ClinicalTrials.gov February 6, 2020. It appears that the first investigator (PI) was then the Pr Yeming Wang, head of the Department of Pulmonary and Critical Care Medicine of the China-Japan Friendship Hospital in Beijing. Note that the first investigator, is the highest person in the hierarchy of responsibility of a clinical trial. Sometimes this responsibility is shared between 2 co-principal investigators.
Normally, the list of other investigators is made up of investigators, researchers working in the hospitals, where are treated the patients cared for. It is very strange that the list of investigators included in this study are three individuals whose affiliations are not hospitals of Wuhan, but are located in the USA and in Europe with : Pr Thomas Jaki , university of Lancaster, the Pr Frederick Hayden of the University of Virginia School of Medicine and professor Peter Horby from the University of Oxford !
In fact, the presence of each of these 3 persons has played a key role in the development of the test phase 3 of the remdésivir and its publication in the prestigious Lancet. First of all, in regards to the statistician Thomas Jaki, we may ask why, knowing the susceptibility of China in matters of sovereignty, the statistical plan of the study has been conducted by a researcher not affiliated with a research institute of chinese so that it was a test that was thus concerned with chinese patients in the first place.
We recall in this respect that the open borders policy of the WHO has been a contributing factor to what the COVID-19 spreads uncontrollably, in any case very quickly, around the world. For this, a statistical plan in good and due form, designed by an expert in the western, could give the trial an international dimension. Do not doubt that the chinese scholars would have been fully competent to establish a statistically reliable.
The second key person of the study, we could almost call ” the mule “, is professor Frederick Hayden , for the simple reason that it is affiliated with a research hospital in the USA, and that the trial could receive an official registration number on ClinicalTrial.gov (NCT04257656) after review and acceptance of the u.s. health authorities. It would have been impossible to get that sesame credibility without an institute involved in a territory of the USA. Such an identification allows, in principle, to ensure that the trial protocol is established according to criteria in line with the best clinical practices international, but most of all, to make perceive westernized. It is necessary to know, on the other hand, that the policy hyper-rigorous ethics of the Lancet, necessarily requires, to publish the results of a clinical trial, a registration number NCT north american or EUDRACT european.
Finally, the third key person is the professor Peter Horby, director of the Centre for Tropical Medicine and Global Health at Oxford University. This person has the role, the more disorder, because in a mysterious way the Pr Horby is past investigator simple to principal investigator, before the Pr Yeming Wang, in the modified version of the protocol filed on ClinicalTrials.gov on April 15, 2020 ! Although everything indicates that he played a role we can not establish with certainty the relationship of Big Pharma, in this case Gilead, and the world of medical research is profound. The network of influence of Big Pharma form a nebula of interests and the taking of cross-shareholdings with players who know each other more or less informal and are co-opted by exchanging services. There is less need now to directly subsidize a clinical trial to get the desired result. The test NCT04257656 is the perfect illustration.
Note that the Pr Horby is a medical researcher recognized in Great Britain. It was already made known during the Ebola epidemic in West Africa that had raged between 2013 and 2016. He was in charge of conducting a clinical trial in order to rapidly identify candidate molecules to become effective treatments, and acceptable toxicity. We refer the reader to a complete record of the conflict of interest underlying in the conclusions of the trial british Recovery, on the arm of the study regarding the hydroxychloroquine, where the Pr Horby has also held a role of principal investigator. The academic position and the positions occupied by the Pr Horby, enable him, no doubt, have what is called vulgarly the people and certainly the ear of the editors of the Lancet.
Big Pharma, by the intermediary of relay academic well-oiled that we have begun to highlight here and in a previous case, may organize a clinical trial and publish in a newspaper of great influence among decision-makers of public health issues such as the Lancet, despite the fact that the health product tested does not exhibit any therapeutic activity significant ! This process is all the more objectionable as it is realized that the physiological variability between Europe and Asia prevent to draw conclusions on medical one continent to another ; problem is well known since a long time.
Turf war between USA and China
When the cloth burns between two rival nations rien ne va plus and the friends of yesterday become the enemies of this : the escape organized by the WHO of the anticipated results, negative test chinese on the remdésivir of Gilead comes 23 April, just 1 week after the announcement (15 April) by the president Trump to suspend the u.s. contribution to this organization !
This unfortunate double accident along the route between China and the USA is not the fruit of chance and one can even say with a hint of irony that it is a long tradition of communication between the two giant geopolitical, brothers enemies. The technique is well-rehearsed : it is to be transported on a space computer access public (internet site, or space non-protected transfer of files) confidential documents to a d-day and h-hour, given that only the recipient knows. And : “oops ! Damn, chief, you made a mistake ” … This technique of non-verbal communication has already acquired its letters of nobility in the past. 25 years ago, a physicist of chinese used on the site ultra-secret Los Alamos had leaked by mistake, the plans of the last-born of the nuclear submarines attack us.
All this to say that the test in china was a trial to which Americans (Gilead) were standing a lot as the centerpiece of propaganda in their promotional campaigns, flash remdésivir during the epidemic. The Chinese, meanwhile, had the cure, because they had already understood that they soigneraient their patients early and preventively with the stroke of antivirals generic hydroxychloroquine.
Despite the failure of this advert murder on the WHO website the union university friends of Big Pharma, as we have described in the previous section, has been able to mobilize without dismount, and continued with its plan to promote academic remdésivir.
Author(s): The Citizens ‘ group for FranceSoir